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Abstract
Aim: To prospectively determine the role of platelet glycoprotein IIIa (GP IIIa) gene PlA1/PlA2
polymorphism on the long-term clinical outcome in patients with coronary artery disease
undergoing coronary stenting.
Design and setting: Prospective observational study in the University Hospital of Caen (France).
Patients and methods: 1 111 symptomatic consecutive Caucasian patients treated with
percutaneous coronary intervention including stent implantation underwent genotyping for GP IIIa
PlA1/A2.
Main outcome measures: Long-term clinical outcome in terms of the rate of major adverse
cardiac events (MACE, ie death from any cause, non-fatal Q wave or non Q wave myocardial
infarction, and need for coronary revascularisation) was obtained and subsequently stratified
according to the GP IIIa PlA1/A2 polymorphism.
Results: Three groups of patients were determined according to the GP IIIa PlA1/A2
polymorphism (71.6% had the A1/A1, 25.8% had the A1/A2 and 2.6% had the A2/A2 genotype).
These three groups were comparable for all clinical characteristics including sex ratio, mean age,
vascular risk factors, previous coronary events, baseline angiographic exam, indication for the
percutaneous coronary intervention and drug therapy). The incidence of MACE was similar in
these 3 groups of patients during a mean follow-up period of 654+/-152 days. Independent risk
factors for MACE were a left ventricular ejection fraction < 40%, absence of treatment with a beta-
blocker and absence of treatment with an angiotensin converting enzyme inhibitor during follow-
up.
Conclusion: The GP IIIa PlA1/A2 polymorphism does not influence the clinical long-term
outcome in patients with symptomatic coronary disease undergoing percutaneous coronary
intervention with stent implantation.
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Many previous studies have shown evidence for a genetic
predisposition in coronary artery disease (CAD) and some
of the several tested single polymorphisms seem to be
implicated [1]. The glycoprotein IIb/IIIa (GPIIb/IIIa) is a
platelet membrane receptor for fibrinogen and von Wille-
brand factor. Glycoprotein IIIa (GPIIIa) is believed to play
a central role in atherothrombosis and is a key element in
platelet aggregation [2,3]. The A1/A2 GPIIIa polymor-
phism [4] can influence both platelet activation and
aggregation [5-7] and affects post occupancy signalling by
the platelet fibrinogen receptor IIb/IIIa [8]. In vitro antiag-
gregation by abciximab was reduced in platelets with the
PlA2 polymorphism [9]. Although the Framingham Off-
spring Study showed heightened platelet aggregability
among patients with PlA2 allele [5], the clinical impact of
this polymorphism remains unclear despite many case-
control studies [10-15], many observational studies [16-
22] and 3 meta-analyses [23-25].
We report here our findings on the role of GP IIIa PlA1/A2
polymorphism based on long-term clinical outcome (>
18 months) of a large observational study of patients
undergoing percutaneous coronary intervention (PCI)
with successful coronary stenting.
Materials and methods
Subjects
During a period of 18 months (November 1996 to April
1998), 1 111 consecutive Caucasian patients with estab-
lished CAD were prospectively enrolled in this observa-
tional study. This study complies with the declaration of
Helsinki and all patients gave their written informed con-
sent. PCI was considered to be successful if residual sten-
osis was < 30% by visual estimation. Diabetes was defined
by either self-reporting and current use of diabetic medi-
cations or if fasting glycemia was greater than 1.26 g/l on
two measurements. Dual antiplatelet therapy, using aspi-
rin and ticlopidine, was systematically used for at least
one month following coronary stenting. Criteria for non
inclusion were: age under 18 years, non-Caucasian,
known neoplasia, refusal to participate, inability to attend
follow-up and failure to extract or amplify desoxyribonu-
cleic acid (DNA). Among the 1111 patients, DNA could
not be amplified in 66 (6.3%) patients, and 95 (9.1%)
patients were lost to follow-up (for 13 of them, DNA
could not be amplified). The remaining 963 patients con-
stituted the study cohort.
Endpoints
The primary endpoint was the composite of major adverse
coronary events (MACE) including death from any cause,
non-fatal Q wave or non Q wave MI, and need for coro-
nary revascularisation by means of PCI or coronary artery
bypass graft (CABG). MACE was analyzed as an aggregate
endpoint and was defined before the study began. Sec-
ondary endpoints were the individual analysis of each
component of the primary endpoint: total mortality,
revascularization (PCI, CABG), and acute coronary syn-
dromes.
Genetic analysis
A blood sample was obtained at the end of the endovas-
cular intervention after stent implantation. Genomic
DNA was prepared from peripheral lymphocytes by the
salt precipitation method [26]. The PlA1/A2 alleles of the
GP IIIa gene were identified on the basis of MspI enzyme
site restriction analysis after amplification of a 476 base
pairs GP IIIa fragment (sens amorce 5'-ATA-AGC-TTA-
GCT-ATT-GGG-AAG-TGG-TAG-GGC-CTG-3', antisens
amorce 5'-CTT-CTG-ACT-CAA-GTC-CTA-ACG-3'). The
GP IIIa gene was amplified using the polymerase chain
reaction (PCR) method. Each amplification product was
verified on an agarose gel. Amplification results in a 476
base pairs (bp) fragment. Digestion was obtained with
Msp1 enzyme and digestion products were visualized on
4% nusieve gel: PlA1/A1 genotype results in 2 bands (279
bp and 197 bp), PlA2/A2 in 3 bands (197, 173 and 106
bp) and PlA1/A2 in 4 bands (279 bp,197 bp,173 bp
and106 bp). As an additional quality-control measure,
masked standards were added randomly to DNA samples
received at the genotyping laboratory. All these samples
were interpreted accurately.
Follow-up
Follow-up was obtained by a questionnaire filled in dur-
ing a phone call conducted by a trained physician. No
scheduled time interval was specified but follow-up was at
least 6 months after the successful coronary stenting pro-
cedure. Events were verified by contacting the patient's
primary physician. Medical records and death certificates
were also reviewed. The clinical follow-up was performed
in a blind manner with respect to patient's genetic status.
Statistical analysis
Baseline characteristics of the study population are pre-
sented as counts and percentages for categorical variables
and as means for continuous variables. Differences in per-
centages were evaluated by the χ2 test, and means by vari-
ance analysis. Validity conditions were checked for each
comparison. No striking deviation from the Hardy-Wein-
berg equilibrium was observed in the distribution of GP
IIIa PlA1/A2 polymorphism (p < 0.5). Univariate survival
analysis with the Kaplan-Meier method and the log rank
test were used to compare genotype groups. Significant
variables (p < 0.20) in the univariate analysis were further
examined in the multivariate model. Cox proportional
hazards models were used in order to identify prognosis
factors related to survival and PlA1/A2 GP IIIa polymor-
phism. The relative risks are given with 95% confidencePage 2 of 8
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All p values were two-tailed. All calculations were per-
formed with SPSS Professional Statistics 13.0 (SPSS Inc,
Chicago, Illinois, USA).
Results
Baseline characteristics of the patients
The study population (n = 963) consisted of 779 males
(80.9%) and 184 females (19.1%). The mean age was
64.4 ± 11.2 years (30.8–90.9). There were no statistically
significant differences in baseline clinical characteristics
(vascular risk factors, medical history, indication for PCI,
angiographic characteristics (left ventricular ejection frac-
tion (LVEF) and number of diseased coronary arteries)
and drug therapy at inclusion in the 3 groups of genotypes
(Table 1). There were no statistically significant differ-
ences in baseline characteristics between patients with fol-
low-up and those without follow-up. One third of
patients had an angiotensin converting enzyme (ACE)
inhibitor and/or a statin at inclusion. At least half of
patients had a beta-blocker at inclusion. The study popu-
lation was mainly treated for acute MI (28.8%) or unsta-
ble angina (37.4%).
Frequencies of alleles and genotypes
The frequencies of the A1 and A2 alleles were 84.5% and
15.5%, respectively. The frequencies of the A1/A1
(71.6%), A1/A2 (25.8%) and A2/A2 (2.6%) genotypes
were virtually identical (Table 2) to those predicted by the
Hardy-Weinberg equilibrium (Stranchan 96). There were
no statistically significant differences in genotypes (p =
0.229) between patients with follow-up and those with-
out follow-up.
Clinical follow-up of patients
Follow-up was mainly obtained between 7 and 24
months after inclusion. Mean follow-up was 654 ± 152
days. The primary clinical end point (MACE) was reached
Table 1: Baseline patient characteristics according to Glycoprotein IIIa (GP IIIa) polymorphism









Male sex (%) 80.9 82.7 64 0.077
Age (mean ± SD, years) 64.4 ± 11.2 64.4 ± 11.4 66.2 ± 10.3 0.717
Age ≥ 65 years (%) 53.9 51.6 64 0.470
Medical history
Hypertension (%) 42.0 43.1 32 0.560
Diabetes mellitus (%) 12.3 14.1 12 0.763
Hypercholesterolemia (%) 51.6 50.4 56 0.512
Past or current smokers (%) 50.6 53.2 40 0.417
Body Mass Index>25 (kg/m2) (%) 63.5 66.1 52 0.293
Family history of CAD (%) 27.8 29.8 24 0.755
Prior MI (%) 31.2 30.2 28 0.915
Prior PCI (%) 13.0 15.3 0 0.065
Prior CABG (%) 10 8.1 0 0.204
Indication for PCI
Stable angina (%) 14.3 18.1 16 0.752
Unstable angina (%) 38.3 35.9 28
Acute MI (%) 29.3 27.0 32
Post MI (%) 11.4 12.1 16
Other (%) 4.5 5.2 8
Angiographic characteristics
LVEF < 40% (%) 15.7 16.1 8 0.716
Single vessel disease (%) 45.4 42.7 32 0.576
Two-vessel disease (%) 32.2 35.5 36
Three-vessel disease (%) 22.5 21.8 32
Therapy at inclusion
ACE inhibitor (%) 32.3 33.1 44 0.481
Beta-blocker (%) 56.1 56.0 80 0.060
Statin (%) 35.2 33.5 32 0.864
ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; 
MI, myocardial infarction; PCI, percutaneous coronary intervention.Page 3 of 8
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A1/A2 and A2/A2 genotypes respectively, with no statisti-
cally significant difference between the groups (Table 2).
Table 2 details the frequencies of the components of
MACE. No difference was seen in genotype distribution.
Kaplan Meier analysis showed that patients of the 3
groups of genotypes had the same probability of MACE (p
= 0.777), death (p = 0.076, figure 1), acute MI (p = 1.000),
unstable angina (p = 0.095) and revascularisation (p =
0.522 for PCI, p = 0.822 for CABG) during the entire fol-
low-up period. Mortality rates were 4.8%, 8.1% and 0.0%
in patients with A1/A1, A1/A2 and A2/A2 genotypes
respectively with no significant difference between the
groups (Table 2). A1/A2 GP IIIa polymorphism was not
found to be an independent predictor of MACE or death
after coronary stenting. MACE and death occurred signifi-
cantly more often if LVEF was < 40% (p = 0.012 and p =
0.022 respectively), if patients received no statin (p =
0.031 and p = 0.017 respectively), no ACE inhibitor (p <
0.001 for both) or no beta-blocker (p < 0.001 for both)
during follow-up (Tables 3 and 4). In addition, death
occurred more often in patients ≥ 65 years (p = 0.002), if
patients received no beta-blocker at inclusion (p = 0.011),
if no PCI was performed during follow-up (p = 0.008),
and if CABG was necessary during follow-up (p = 0.047)
(Table 4).
Multivariate analysis (Table 5)
A multivariate analysis was performed by adjusting for
several potential confounding factors. We embedded in
Table 3: Univariate analysis of MACE in the subgroups of the study population
MACE
Subgroups n Survival (%) p
Demographic characteristics
Males/Females 779/184 78.8/80.6 0.631
Age ≥ 65/< 65 years 516/447 79.4/78.6 0.622
Medical history
Hypertension yes/no 405/558 77.1/80.2 0.852
Diabetes mellitus yes/no 123/840 73.7/79.9 0.481
Hypercholesterolemia yes/no 465/498 83.0/76.0 0.124
Past or current smokers yes/no 491/472 76.5/81.9 0.380
BMI ≥ 25/< 25 (kg/m2) 619/344 79.1/78.7 0.253
Family history of MI yes/no 272/691 78.5/79.4 0.401
Prior MI yes/no 297/666 82.0/77.9 0.292
Prior PCI yes/no 128/835 76.3/79.6 0.988
Prior CABG yes/no 89/874 71.3/79.9 0.564
GP III a polymorphism
A1A1/A1A2/A2A2 690/248/25 78.3/80.6/91.7 0.777
Coronary artery vessels diseased
Single+two-/three-vessel disease 746/217 80.2/75.3 0.109
LVEF ≥ 40%/< 40% 808/155 80.4/73.5 0.012
Therapy
ACE inhibitor yes/no 316/647 69.2/81.9 0.062
Beta-blocker yes/no 546/417 74.9/81.3 0.262
Statin yes/no 334/629 76.5/79.2 0.770
Therapy during follow-up
Statin yes/no 462/501 82.6/76.2 0.031
ACE inhibitor yes/no 338/625 89.3/73.3 < 0.001
Beta-blocker yes/no 580/383 86.5/69.3 < 0.001
ACE, angiotensin converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; PCI, percutaneous coronary intervention.









MACE % 13.6 14.1 8.0 0.730
Death % 4.8 8.1 0.0 0.083
Revascularisation
PCI % 15.7 4.1 8.0 0.522
CABG % 2.8 3.6 4.0 0.822
Unstable angina % 1.7 4.0 4.2 0.095
Acute MI % 0.6 0.4 0.0 1.000
CABG, coronary artery bypass graft; MACE, major adverse coronary 
event; MI, myocardial infarction; PCI, percutaneous coronary 
intervention.Page 4 of 8
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value of less than 0.20 in the univariate analysis (clinical
data, angiographic findings, genetic markers, conven-
tional risk factors, treatments). Mortality rate was low in
patients having the A2/A2 genotype. Independent risk fac-
tors for MACE after PCI were a LVEF < 40% (p = 0.001),
absence of treatment with beta-blocker (p < 0.001) and
absence of treatment with an ACE inhibitor (p < 0.001)
during follow-up. Table 5 shows the hazard ratios and the
95% confidence intervals for these independent prognos-
tic variables. The results were identical for death (Table 5).
Discussion
Our prospective observational study showed that GPIIIa
A1/A2 polymorphism would have no influence on long-
term risk of MACE in patients having proven symptomatic
CAD treated by PCI with stent implantation (bare metal
stent era). This message is of clinical relevance despite
recent changes in stenting procedure and adjunctive med-
ication. Multivariate analysis showed that LVEF < 40%,
and absence of treatment with beta-blocker or ACE inhib-
itor during follow-up were independent predictors of
MACE and death in such patients. In univariate analysis,
mortality was also significantly higher in patients ≥ 65
years at inclusion and those who had no revascularization
during follow-up.
The role of the GP IIIa PlA1/A2 polymorphism remains
controversial. It depends on the design of the studies, the
characteristics of the patients included, the end-points
used and the duration of follow-up. The case-control stud-
ies performed did not show any evidence of a role for the
Table 4: Survival rates in the subgroups of the study population
Death
Subgroups n Survival (%) p
Demographic characteristics
Males/Females 779/184 94.5/93.3 0.473
Age ≥ 65/< 65 years 516/447 92.1/96.7 0.002
Medical history
Hypertension yes/no 405/558 94.3/94.2 0.927
Diabetes mellitus yes/no 123/840 94.1/94.3 0.939
Hypercholesterolemia yes/no 465/498 95.8/92.8 0.069
Past or current smoking yes/no 491/472 95.3/93.2 0.152
BMI ≥ 25/< 25 (kg/m2) 619/344 95.0/93.3 0.246
Family history of MI yes/no 272/691 95.8/93.6 0.209
Prior MI yes/no 297/666 95.9/93.5 0.179
Prior PCI yes/no 128/835 96.0/94.0 0.396
Prior CABG yes/no 89/874 91.9/94.5 0.323
GP III a polymorphism
A1A1/A1A2/A2A2 690/248/25 95.0/91.8/100.0 0.076
PCI indication
Stable angina 152 97.3 0.572
Unstable angina 365 94.3
MI 282 94.1
Post MI 117 92.7
Other 47 93.0
Coronary artery vessels diseased
Single+two-/three-vessel disease 746/217 94.9/92.1 0.185
LVEF ≥ 40%/< 40% 808/155 95.0/90.5 0.022
Therapy
ACE inhibitor yes/no 316/647 94.4/94.1 0.886
Beta-blocker yes/no 546/417 96.0/92.0 0.011
Statin yes/no 334/629 95.9/93.3 0.114
Revascularisation during follow-up
PCI yes/no 145/818 99.3/93.4 0.008
CABG yes/no 29/934 86.1/94.5 0.047
Therapy during follow-up
Statin yes/no 462/501 96.2/92.5 0.017
ACE inhibitor yes/no 338/625 100.0/91.1 < 0.001
Beta-blocker yes/no 580/383 99.8/85.8 < 0.001
ACE, angiotensin converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; PCI, percutaneous coronary intervention.Page 5 of 8
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(MI), premature MI or non-fatal premature MI [10-15].
Some of the observational studies suggested that PlA1/A2
polymorphism may be associated with an increased risk
of CAD [16] and restenosis following coronary revascular-
isation [17-19]. Other observational studies suggested no
association between GP IIIa polymorphism and CAD
[20,21] or restenosis [22]. The first meta-analysis of rele-
vant studies (10638 individuals) showed that the PlA2
variant of GP IIIa was not an inherited risk factor for acute
coronary syndromes [23]. In the other two meta-analyses
of mostly case-control studies (28503 individuals), PlA2
variant was a weak inherited risk factor for acute coronary
syndromes and restenosis [24,25]. In the meta-analysis of
Di Castenuovo et al., the odds ratio was higher in the 4
studies testing stent implantation (1.37, 95% CI: 1.11–
1.70) than in the 2 studies testing percutaneous coronary
artery dilatation (1.14, 95% CI: 0.86–1.63) [24]. This
meta-analysis included case-control studies with short fol-
low-up (≤ 6 months), and the combined clinical end-
point, MACE, was used in only one study [24,27].
Although slight, an average increase of the risk by 10% in
a multifactorial disease such as CAD cannot be dis-
counted.
The design of observational studies like ours is less contro-
versial than that of case-control studies. In two observa-
tional studies using the clinical end point of MACE, the
impact of the A2 allele was statistically significant [18,19].
The design of these 2 studies was similar to the design of
our study but the follow-up was shorter (30 days and 6
months). In the first one (1 759 patients, follow-up of 30
days), A2A2 carriers experienced significantly more MACE
(p = 0.06), more death or MI (p = 0.02) and more stent
thrombosis (p = 0.002) [18]. In the second one (650
patients), there was no significant difference in A2 carriers
for MACE after a follow-up of 6 months. Nevertheless, the
number of MIs was significantly higher for A2 carriers at
day 30 (p = 0.007). Restenosis rate was also higher in the
A2 carriers (p = 0.06) but the difference was not signifi-
cant in the multivariate analysis [19].
Our study is a prospective observational study and has the
advantage of being of relatively large size (n = 963). The
size of the 3 groups, the follow-up period used and the
median survival time assessed at 5 years allows calcula-
tion of a power of at least 0.80 for our study to exclude an
effect of the studied polymorphism. The primary end-
point used was a clinical one combining MACE (death
(from any cause), non-fatal Q wave MI, proven unstable
angina, and need for coronary revascularisation). The
item "need for coronary revascularisation" would not
have induced a survival bias because it corresponded to
Death from any cause after revascularisation in the study populati n according to PlA1/A2 GP III  polymorphism (p < 0.076)Fig re 1
Death from any cause after revascularisation in the study 
population according to PlA1/A2 GP III a polymorphism (p < 
0.076).
Table 5: Independent risk factors for MACE and death in the study population (multivariate analysis, A1A1 (n = 690), A1A2 (n = 248), 
A2A2 (n = 25))
MACE * Death **
RR 95% CI p RR 95% CI p
LVEF < 40% 2.07 1.37–3.13 0.001 2.81 1.53–5.16 0.001
Follow-up
Beta-blocker no/yes 2.46 1.70–3.56 < 0.001 10.64 4.54–24.94 < 0.001
ACE inhibitor no/yes 2.63 1.65–4.18 < 0.001 8.91 2.74–28.98 < 0.001
* For MACE, Cox multivariable model included: hypercholesterolemia, coronary artery disease extent, LVEF, treatments during follow-up (statin 
and/or betablocker and/or ACE inhibitor), GP IIIa polymorphism. Other variables were not statistically significant in the univariate model.
** For death, Cox multivariable model included: age, hypercholesterolemia, past or current smoking, prior MI, family history of MI, coronary artery 
disease extent, LVEF, revascularisations during follow-up (PCI, CABG), treatment during follow-up (ACE inhibitor, betablocker, statin), GP IIIa 
polymorphism. Other variables were not statistically significant in the univariate model.
ACE, angiotensin converting enzyme; CABG, coronary artery bypass graft; CI, confidence interval; LVEF, left ventricular ejection fraction; MACE, 
major adverse coronary event; MI, myocardial infarction; PCI, percutaneous coronary intervention; RR, relative risk.Page 6 of 8
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not performed systematically) and the mortality rate was
similar in the different groups of patients. Furthermore
the follow-up was long (mean 2.1 years) compared with
previous observational studies with stent implantation
[18,19]. The population in our study was a relatively high
risk population: 13.6% of patients reached primary com-
posite clinical end point and 5.5% died.
On the other hand our study has some limitations. Firstly
our study was conducted in a single University Hospital
characterised by regional environmental influences. The
result may be different if recruitment were national. Sec-
ondly the number of A2/A2 patients was small (n = 25)
explaining the inability to draw any firm conclusions for
the A2/A2 genotype. It is possible that the impact of A2/
A2 genotype on MACE has been underestimated. In order
to confirm our result it would be necessary to enlarge this
study with a bigger number of patients and particularly
A2/A2 patients. Thirdly, patients were perhaps not young
enough to allow us to show a statistically significant dif-
ference: mean age was 64.4 ± 11.2 years (30.8–90.9). Nev-
ertheless the mean age was similar to that of previous
studies [18,19]. Lastly, the number of DNA amplification
failures and patients lost to follow-up was high. Despite
the high number, this is not likely to have affected the
results because clinical characteristics and genotypes (p =
0.229) of patients with follow-up and those who were lost
to follow-up did not differ.
Multivariate analysis showed that LVEF < 40%, and
absence of treatment with beta-blocker or ACE inhibitor
during follow-up were independent predictors of MACE
and death in such patients. These results are not surprising
given the known beneficial effects of these drugs in CAD
[28-30]. The non-prescription of these drugs may have
been due to greater associated co-morbidities. In univari-
ate analysis, mortality was significantly higher in patients
≥ 65 years at inclusion and in those who had no PCI dur-
ing follow-up. The significantly higher rate of mortality
for the patients who had no PCI during follow-up may be
explained by silent ischemia. Patients had no systematic
angiogram during follow-up and several re-stenoses may
have occurred and may not have been diagnosed.
Conclusion
Based on our results, the PlA1/A2 GP IIIa polymorphism
could not be used as a risk marker of MACE in sympto-
matic coronary heart disease patients. Our study suggests
that the A1/A2 polymorphism of GP IIIa is not a major
pathophysiological factor in patients who have had coro-
nary artery stenting.
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